Furthermore, durvalumab, an anti-PD-L1 antibody, is being investigated in a phase Ib/II study in combination with tremelimumab in gastric cancer (https://clinicaltrials.gov/ct2/show/NCT02340975). The gene discussed is CD274; the disease is gastric cancer.